Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

Low magnification confocal microscopy of tumor angiogenesis.

McNamara G, Yanai A, Khankaldyyan V, Laug WE, Boden J, Webster K, Li Y, Wen R.

Methods Mol Biol. 2014;1075:149-75. doi: 10.1007/978-1-60761-847-8_6. Erratum in: Methods Mol Biol. 2014;1075: E1-3.

PMID:
24052350
2.

Plasminogen activator inhibitor-1 protects endothelial cells from FasL-mediated apoptosis.

Bajou K, Peng H, Laug WE, Maillard C, Noel A, Foidart JM, Martial JA, DeClerck YA.

Cancer Cell. 2008 Oct 7;14(4):324-34. doi: 10.1016/j.ccr.2008.08.012.

3.

A non-invasive, in vivo technique for monitoring vascular status of glioblastoma during angiogenesis.

Saxena V, Gonzalez-Gomez I, Laug WE.

Technol Cancer Res Treat. 2007 Dec;6(6):641-50.

PMID:
17994795
4.

A noninvasive multimodal technique to monitor brain tumor vascularization.

Saxena V, Gonzalez-Gomez I, Laug WE.

Phys Med Biol. 2007 Sep 7;52(17):5295-308. Epub 2007 Aug 16.

PMID:
17762087
5.

Effect of the angiogenesis inhibitor Cilengitide (EMD 121974) on glioblastoma growth in nude mice.

Yamada S, Bu XY, Khankaldyyan V, Gonzales-Gomez I, McComb JG, Laug WE.

Neurosurgery. 2006 Dec;59(6):1304-12; discussion 1312.

PMID:
17277694
6.

In vivo testing of Renilla luciferase substrate analogs in an orthotopic murine model of human glioblastoma.

Otto-Duessel M, Khankaldyyan V, Gonzalez-Gomez I, Jensen MC, Laug WE, Rosol M.

Mol Imaging. 2006 Apr-Jun;5(2):57-64.

PMID:
16954019
7.

Longitudinal microPET imaging of brain tumor growth with F-18-labeled RGD peptide.

Chen X, Park R, Khankaldyyan V, Gonzales-Gomez I, Tohme M, Moats RA, Bading JR, Laug WE, Conti PS.

Mol Imaging Biol. 2006 Jan-Feb;8(1):9-15.

PMID:
16315003
8.

A method to accurately inject tumor cells into the caudate/putamen nuclei of the mouse brain.

Yamada S, Khankaldyyan V, Bu X, Suzuki A, Gonzalez-Gomez I, Takahashi K, McComb JG, Laug WE.

Tokai J Exp Clin Med. 2004 Dec;29(4):167-73.

PMID:
15717488
9.

Endothelial apoptosis induced by inhibition of integrins alphavbeta3 and alphavbeta5 involves ceramide metabolic pathways.

Erdreich-Epstein A, Tran LB, Cox OT, Huang EY, Laug WE, Shimada H, Millard M.

Blood. 2005 Jun 1;105(11):4353-61. Epub 2005 Feb 10.

10.

Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.

Chen X, Hou Y, Tohme M, Park R, Khankaldyyan V, Gonzales-Gomez I, Bading JR, Laug WE, Conti PS.

J Nucl Med. 2004 Oct;45(10):1776-83.

11.

Hypertonic saline impedes tumor cell-endothelial cell interaction by reducing adhesion molecule and laminin expression.

Shields CJ, Winter DC, Wang JH, Andrews E, Laug WE, Redmond HP.

Surgery. 2004 Jul;136(1):76-83.

PMID:
15232542
12.

MicroPET imaging of brain tumor angiogenesis with 18F-labeled PEGylated RGD peptide.

Chen X, Park R, Hou Y, Khankaldyyan V, Gonzales-Gomez I, Tohme M, Bading JR, Laug WE, Conti PS.

Eur J Nucl Med Mol Imaging. 2004 Aug;31(8):1081-9. Epub 2004 Apr 29.

PMID:
15118844
13.

Species-specific urokinase receptor ligands reduce glioma growth and increase survival primarily by an antiangiogenesis mechanism.

Bu X, Khankaldyyan V, Gonzales-Gomez I, Groshen S, Ye W, Zhuo S, Pons J, Stratton JR, Rosenberg S, Laug WE.

Lab Invest. 2004 Jun;84(6):667-78.

14.

18F-labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesis.

Chen X, Park R, Shahinian AH, Tohme M, Khankaldyyan V, Bozorgzadeh MH, Bading JR, Moats R, Laug WE, Conti PS.

Nucl Med Biol. 2004 Feb;31(2):179-89.

PMID:
15013483
15.

Micro-MRI at 11.7 T of a murine brain tumor model using delayed contrast enhancement.

Moats RA, Velan-Mullan S, Jacobs R, Gonzalez-Gomez I, Dubowitz DJ, Taga T, Khankaldyyan V, Schultz L, Fraser S, Nelson MD, Laug WE.

Mol Imaging. 2003 Jul;2(3):150-8. Erratum in: Mol Imaging. 2003 Oct;2(4):follwoing table of contents.

PMID:
14649058
16.
17.

Time course of bioluminescent signal in orthotopic and heterotopic brain tumors in nude mice.

Burgos JS, Rosol M, Moats RA, Khankaldyyan V, Kohn DB, Nelson MD Jr, Laug WE.

Biotechniques. 2003 Jun;34(6):1184-8.

18.

In vitro and in vivo evaluations of the tyrosine kinase inhibitor NSC 680410 against human leukemia and glioblastoma cell lines.

Avramis IA, Christodoulopoulos G, Suzuki A, Laug WE, Gonzalez-Gomez I, McNamara G, Sausville EA, Avramis VI.

Cancer Chemother Pharmacol. 2002 Dec;50(6):479-89. Epub 2002 Oct 17.

PMID:
12451475
19.

Soluble interleukin 6 receptor (sIL-6R) mediates colonic tumor cell adherence to the vascular endothelium: a mechanism for metastatic initiation?

Dowdall JF, Winter DC, Andrews E, Laug WE, Wang JH, Redmond HP.

J Surg Res. 2002 Sep;107(1):1-6.

PMID:
12384057
20.

alpha v-Integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin.

Taga T, Suzuki A, Gonzalez-Gomez I, Gilles FH, Stins M, Shimada H, Barsky L, Weinberg KI, Laug WE.

Int J Cancer. 2002 Apr 10;98(5):690-7.

21.

Plasminogen activator inhibitor-1 promotes angiogenesis by stimulating endothelial cell migration toward fibronectin.

Isogai C, Laug WE, Shimada H, Declerck PJ, Stins MF, Durden DL, Erdreich-Epstein A, DeClerck YA.

Cancer Res. 2001 Jul 15;61(14):5587-94.

22.

Tumor cell adhesion to endothelial cells is increased by endotoxin via an upregulation of beta-1 integrin expression.

Andrews EJ, Wang JH, Winter DC, Laug WE, Redmond HP.

J Surg Res. 2001 May 1;97(1):14-9.

PMID:
11319874
23.

Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(v) integrin antagonist.

MacDonald TJ, Taga T, Shimada H, Tabrizi P, Zlokovic BV, Cheresh DA, Laug WE.

Neurosurgery. 2001 Jan;48(1):151-7.

PMID:
11152340
24.

The plasminogen-plasminogen activator (PA) system in neuroblastoma: role of PA inhibitor-1 in metastasis.

Sugiura Y, Ma L, Sun B, Shimada H, Laug WE, Seeger RC, DeClerck YA.

Cancer Res. 1999 Mar 15;59(6):1327-36.

25.

Urokinase induces receptor mediated brain tumor cell migration and invasion.

MacDonald TJ, DeClerck YA, Laug WE.

J Neurooncol. 1998 Dec;40(3):215-26.

PMID:
10066093
26.

Detection of brain tumor invasion and micrometastasis in vivo by expression of enhanced green fluorescent protein.

MacDonald TJ, Tabrizi P, Shimada H, Zlokovic BV, Laug WE.

Neurosurgery. 1998 Dec;43(6):1437-42; discussion 1442-3.

PMID:
9848858
27.
28.

Proteases and protease inhibitors in tumor progression.

DeClerck YA, Imren S, Montgomery AM, Mueller BM, Reisfeld RA, Laug WE.

Adv Exp Med Biol. 1997;425:89-97. Review.

PMID:
9433492
29.

The exon 3 encoded sequence of the intracellular serine proteinase inhibitor plasminogen activator inhibitor 2 is a protein binding domain.

Jensen PH, Jensen TG, Laug WE, Hager H, Gliemann J, Pepinsky B.

J Biol Chem. 1996 Oct 25;271(43):26892-9.

30.

Elevated levels of plasminogen activator inhibitor-1 may account for the altered fibrinolysis by keloid fibroblasts.

Tuan TL, Zhu JY, Sun B, Nichter LS, Nimni ME, Laug WE.

J Invest Dermatol. 1996 May;106(5):1007-11.

31.

Independent regulation of matrix metalloproteinases and plasminogen activators in human fibrosarcoma cells.

Lim YT, Sugiura Y, Laug WE, Sun B, Garcia A, DeClerck YA.

J Cell Physiol. 1996 May;167(2):333-40.

PMID:
8613475
32.
33.
34.

Inhibition of invasion of HT1080 sarcoma cells expressing recombinant plasminogen activator inhibitor 2.

Laug WE, Cao XR, Yu YB, Shimada H, Kruithof EK.

Cancer Res. 1993 Dec 15;53(24):6051-7.

PMID:
8261421
35.

Clonal variation of expression of the genes coding for plasminogen activators, their inhibitors and the urokinase receptor in HT1080 sarcoma cells.

Laug WE, Wang K, Mundi R, Rideout W 3rd, Kruithof EK, Bogenmann E.

Int J Cancer. 1992 Sep 9;52(2):298-304.

PMID:
1325952
36.

Complex expression of the genes coding for plasminogen activators and their inhibitors in HeLa-smooth muscle cell hybrids.

Laug WE, Cao XR, T'Ang A, Pasquale S, Mundy R, Coensgen-Luna M, Weissman B.

Cell Growth Differ. 1992 Mar;3(3):191-7.

37.

Plasminogen activator inhibitor type 1 production by rat type II pneumocytes in culture.

Parton LA, Warburton D, Laug WE.

Am J Respir Cell Mol Biol. 1992 Feb;6(2):133-9.

PMID:
1540377
38.

Chimeric immunoglobulin-T cell receptor proteins form functional receptors: implications for T cell receptor complex formation and activation.

Goverman J, Gomez SM, Segesman KD, Hunkapiller T, Laug WE, Hood L.

Cell. 1990 Mar 23;60(6):929-39.

PMID:
2138514
39.

Plasminogen activator regulation by transforming growth factor-beta in normal and neoplastic human urothelium.

Hiti AL, Rideout WM 3rd, Laug WE, Jones PA.

Cancer Commun. 1990;2(3):123-8.

PMID:
2114167
40.

Isolation of multiple types of plasminogen activator inhibitors from vascular smooth muscle cells.

Laug WE, Aebersold R, Jong A, Rideout W, Bergman BL, Baker J.

Thromb Haemost. 1989 Jun 30;61(3):517-21.

PMID:
2799763
41.

Triple X chromosome constitution and acute nonlymphocytic leukemia.

Ozkaynak MF, Ying KL, Laug WE.

Cancer Genet Cytogenet. 1988 Oct 1;35(1):1-3.

PMID:
3179999
42.
43.

Improved detection of metastatic Ewing's sarcoma with the use of bone marrow scintigraphy.

Jones GR, Miller JH, White L, Laug WE, Shore NA.

Med Pediatr Oncol. 1987;15(2):78-81.

PMID:
3587118
44.

Transient blastemia in phenotypically normal newborns.

Jones GR, Weaver M, Laug WE.

Am J Pediatr Hematol Oncol. 1987 Summer;9(2):153-7.

PMID:
2954483
45.

Inhibition of tumor cell collagenolytic activity by bovine endothelial cells.

DeClerck YA, Laug WE.

Cancer Res. 1986 Jul;46(7):3580-6.

46.

Pulmonary alveolar septal calcinosis causing progressive respiratory failure in acute lymphoblastic leukemia in childhood.

Sinniah D, Landing BH, Siegel SE, Laug WE, Gwinn JL.

Pediatr Pathol. 1986;6(4):439-48.

PMID:
3473456
47.

Endothelial cells degrade extracellular matrix proteins produced in vitro.

Laug WE, Weinblatt ME, Jones PA.

Thromb Haemost. 1985 Aug 30;54(2):498-502.

PMID:
4082085
48.
49.
50.

Effects of X-irradiation on artificial blood vessel wall degradation by invasive tumor cells.

Heisel MA, Laug WE, Stowe SM, Jones PA.

Cancer Res. 1984 Jun;44(6):2441-5.

Supplemental Content

Support Center